Geneos Wealth Management’s Collegium Pharmaceutical COLL Stock Holding History

Geneos Wealth Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,700	Closed	-$30K	–	2112
2022 Q2	$30K	Sell	1,700 -500	-23%	-$8.41K	﹤0.01%	1491
2022 Q1	$44K	Hold	2,200	–	–	﹤0.01%	1439
2021 Q4	$41K	Hold	2,200	–	–	﹤0.01%	1556
2021 Q3	$43K	Buy	+2,200	New	+$47.6K	﹤0.01%	1557
2020 Q4	–	Sell	-4,500	Closed	-$83K	–	2908
2020 Q3	$83K	Hold	4,500	–	–	﹤0.01%	1026
2020 Q2	$73K	Buy	4,500 +1,800	+67%	+$35.2K	﹤0.01%	1053
2020 Q1	$44K	Hold	2,700	–	–	﹤0.01%	1167
2019 Q4	$56K	Hold	2,700	–	–	﹤0.01%	1188
2019 Q3	$30K	Hold	2,700	–	–	﹤0.01%	1418
2019 Q2	$35K	Hold	2,700	–	–	﹤0.01%	1364
2019 Q1	$40K	Sell	2,700 -2,000	-43%	-$32K	﹤0.01%	1242
2018 Q4	$77K	Hold	4,700	–	–	0.01%	920
2018 Q3	$69K	Buy	+4,700	New	+$83.3K	﹤0.01%	1027

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geneos Wealth Management's COLL Position: Q3 2022 in Review

Geneos Wealth Management sold out of Collegium Pharmaceutical (COLL) in Q3 2022, closing a stake of 1,700 shares — an estimated $30K sold.

Geneos Wealth Management first reported a position in COLL in Q3 2018 and held it in 13 quarters. The position peaked at $83K in Q3 2020. 168 funds tracked by Wall St. Rank hold COLL as of Q3 2022.

Geneos Wealth Management reported no remaining Collegium Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Geneos Wealth Management sold 1,700 Collegium Pharmaceutical shares in Q3 2022, an estimated $30K.
Geneos Wealth Management first reported a position in Collegium Pharmaceutical in Q3 2018 and held it in 13 quarters.
Geneos Wealth Management's Collegium Pharmaceutical position peaked at $83K in Q3 2020.
168 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.